CureVac NV is continuing the reshaping of its oncology business following the German group's underwhelming efforts to become a player in the mRNA COVID-19 vaccines space with the acquisition of neoantigen specialist Frame Therapeutics of the Netherlands.
The Tübingen-headquartered group's purchase is valued at €32m and will be paid in CureVac shares. Following a 50% upfront payment,...